Lapahope 250mg tablet |Lapatinib | millionpharma

                    LAPAHOPE 250MG

DESCRIPTION

                                  Lapahope 250mg belongs to class of antineoplastic drugs which prevents the development and spreading of cancer cells all over the body.
Lapahope 250mg tablet is indicated for metastatic breast Lapahope 250mg tablet cancer and spreading after using of other chemotherapy drugs
                         

Lapahope 250mg

INDICATION

                   Lapahope 250mg with combination of capecitabine is indicated for the treatment of advanced breast cancer after the failure of other cancer medicine.
Lapahope 250mg tablet is also combined withLapahope 250mg letrozole is indicated for the treatment postmenopausal women with hormone receptor positive metastatic breast cancer.

MECHANISM OF ACTION

                    Lapahope 250mg is a type of classification called kinase inhibitor and act by intracellular tyrosine kinase. Lapahope prohibits ErbB-forced tumor cell growth in vitro and in various animal models. When combination 5-fluracil with Lapahope 250mg created an additive effect in the 4 tumor cell lines tested. Development inhibits the Lapahope 250mg tablet effect was examined in trastuzumab-conditioned cell lines.
Lapahope 250mg provide selective action against Lapahope 250mg breast cancer cell lines selected for long-term growth in trastuzumab-containing intracellularly. Hormone receptor-positive breast cancer cells (with ER [Estrogen Receptor] and/or Lapahope 250mg tablet PgR [Progesterone Receptor]) that co-express the HER2 bear to be protection against established endocrine therapies. Synchronously Lapahope 250mg hormone receptor-positive breast cancer cellsLapahope 250mg tablet that initially lacks EGFR or HER2 unrecalled these receptor proteins as the tumor becomes resistant to endocrine therapy.

PRODUCT DETAILS

Brand : Lapahope
Ingredients : Lapatinib
Strength : 250 mg
Manufactured : Glenmark Pharma
Package : 30 Tablets

DOSAGE MANAGEMENT

                            The usual dose of Lapahope 250mg for adult suffering HER2 positive metastatic breast cancer (with Xeloda) is 1250mg once daily for 1-21days continuously repeating.
Femora Combination with Lapahope 250mg tablet the dose recommended is 1500mg orally once a day continuously once daily every day.
Take the drug Lapahope 250mg tablet  on an empty stomach (1hr before or 1hr after).

OVERDOSE:

                       If overdose occurs, seek to emergency Lapahope 250mg department or call poison control helpline

PRECAUSION

                   If you are allergic toLapahope 250mg tablet lapatinib, then do not use the drug
  If you had hepatic problem, cardio disease, an electrolytic imbalance then discusses with doctor whether it’s safe to use or not prior toLapahope 250mg tablet Lapahope treatment.
While patients during pregnancy, it should strictly avoid the drug because it harms the unborn baby or cause birth defects.
There is not Lapahope 250mg known whether Lapatinib passes into breast milk.Lapahope 250mg tablet Hence avoid breastfeeding to the infants during Lapahope 250mg tablet treatment

SIDE EFFECT

         Lapahope 250mg tablet will cause mild to moderate side effects in patients. If symptoms cause serious the inform the doctor as soon Lapahope 250mg tablet as possible.

Common side effect of Lapahope 250mg tablets :

                 LumbarLapahope 250mg pain; diarrhae; dry skin; nail of finger toe changes; headache; indigestion problem; decreased appetite; mild hair loss orLapahope 250mg tablet thinning; mouth ulcers; nausea; nosebleed; redness and hands and feet will have tingling; weakness; insomnia; vomiting.

Serious side effect of Lapahope 250mg tablets :

               Severe Lapahope 250mgtightness; difficulty in breathing; unusual bruising or bleeding; unusual itching; yellowing of the eyes or skin; Chest pain; urine will Lapahope 250mg tablet be dark; dizziness or light-headedness; Rapid or irregular heartbeat; pale stools; persistent loss of appetite; severe or persistent cough; severe or Lapahope 250mg tablet persistent diarrhea, nausea, vomiting and skin allergy like itching, rashes, blisters in mouth, face, lip or tongue.

EMAIL         :millionhealthpharmaceuticals@gmail.com

PHONE NO : +91-9940472902

WEBSITE    : https://millionpharma.com/lapahope.php

Erlonat 100mg tablet |Erlotinib | Millionpharma

                    ERLONAT 100MG

DESCRIPTION

                           Erlonat 100mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 100mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.
Erlonat 100mg tablets are prescription medicine,     Erlonat 100mg tabletused only by the patients who have valid prescription

ERLONAT 100MG

INDICATION AND USAGE

                           Erlonat 100mg is primarily indicated for; Non small cell lung cancer: Erlonat 100mg is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat 100mg is involved in     Erlonat 100mg tablet the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlonat 100mg tablet is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat 100mg tablet is used in combination with gemcitabine. In this condition Erlonat 100mg is involved as first line treatment.

WARNING

                               Some of the adverse     Erlonat 100mg tablet effects occur while treating with Erlonat 100mg tablets; Interstitial lung disease Renal impairment Hepatic toxicity     Erlonat 100mg tablet with liver failure Gastrointestinal perforation Bullous &     Erlonat 100mg tablet exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular disorders Embryo fetal toxicity

ERLONAT PHARMACOLOGY

                         Erlonat 100mg tablet has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal     Erlonat 100mg tablet growth factor    Erlonat 100mg tablet receptor. This EGFR is     Erlonat 100mg tablet occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ERLONAT ADME PROPERTY

ABSORPTION

                          The peak    Erlonat 100mg tablet plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its    Erlonat 100mg tablet bioavailability to 100%. The    Erlonat 100mg tablet Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlonat 100mg tablet , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

                        Volume of distribution     Erlonat 100mg tablet of Erlotinib is 232L Human protein binding to Erlotinib 100mg tablet is occurs as 93%.

METABOLISM

                       The metabolism of Erlotinib 100mg is occurs by CYP3A4

ELIMINATION

                       The route of elimination of Erlotinib 100mgmetabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

PRODUCT DETAILS

Brand : Erlonat
Ingredients : Erlotinib
Strength : 100mg
Manufactured : Natco
Package : 30 Tablets

DOSAGE ADMINISTRATION

DOSAGE MANAGEMENT

                           In NSCLC: The recommended dosage is     Erlonat 100mg tablet 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat 100mg is 100mg should be taken    Erlonat 100mg tablet as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Erlonat 100mg Interstitial lung disease, pulmonary failure: Discontinue the Erlonat 100mg therapy In severe hepatic failure: Stop the therapy permanently
In renal impairment: Discontinue the Erlonat 100mg therapy permanently In gastrointestinal perforation and severe diarrhea:     Erlonat 100mg tablet Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive     Erlonat 100mg tablet measures In corneal perforation, therapy should be     Erlonat 100mg tablet discontinuing permanently. Avoid concomitant use of Erlonat 100mg tablet with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECT

SOME SERIOUS ADVERSE EFFECT

                          Renal failure Erlonat 100mg Liver toxicity Erlonat 100mg with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

                         Rash Erlonat 100mg Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Erlonat 100mg Chest pain,    Erlonat 100mg tablet  arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with lipid lowering drugs

DRUG INTERACTION

CYP3A4 INHIBITORS:

                         Concomitant use of Erlonat 100mg with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir,    Erlonat 100mg tablet posaconazole, ritonavir, saquinavir, telithromycin,     Erlonat 100mg tablet voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat 100mg tablet .

IN CYP3A4 INDUCERS:

                     In combination of Erlonat Erlonat 100mg100mg with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlonat 100mg tablet .

CYP1A2 INDUCERS & CIGARETTE SMOKING:

                    Both are decreasing Erlonat 100mg the exposure of Erlotinib, while concomitant with Erlonat 100mg .

GASTRIC REGULATORS:

                  While    Erlonat 100mg tablet concomitant with gastricErlonat 100mg regulators like proton Erlonat 100mgpump inhibitors, H2 receptors    Erlonat 100mg tablet antagonist or antacids, Erlonat 100mgcauses depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib.

ANTICOAGULANTS:

                  In combination of Erlonat 100mgErlonat 100mg with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

PHONE NO     : +91-9940472902

EMAIL ID       : millionhealthpharmaceuticals@gmail.com

WEBSITE        : https://millionpharma.com/erlonat-100mg.php

Tykerb 250 mg (Lapatinib)|novartis|uses,composition,side effects,price in India

                    TYKERB

DESCRIPTION

                                   Tykerb 250mg  belongs to class of antineoplastic drugs which preventsTykerb 250mg  the development Tykerb 250mg tablet and spreading of cancer cells all over the body.
Tykerb 250mg tablet is indicated forTykerb 250mg metastatic breast cancer and spreading after using of other chemotherapy drugs

TYKERB 250MG

 INDICATION

                                   Tykerb 250mg with combination of capecitabine is indicated for the treatment of advanced breast cancer after the failure of other Tykerb 250mg tabletcancer medicine.
Tykerb 250mg tablet is also combined with letrozole is indicated for the treatment postmenopausal women Tykerb 250mg tabletwith hormone receptor positive metastatic breast cancer.

MECHANISM OF ACTION

                              Tykerb 250mg tablet is a type of classification called kinase inhibitor and act by intracellular tyrosine kinase.
Tykerb prohibits ErbB-forced tumor cell growth in vitro and in various animal models. When Tykerb 250mg combination 5-fluracil with
Tykerb 250mg created an additive effect in the 4 tumor cell lines tested. Development inhibitsTykerb 250mg tablet the Tykerbtablet effect were examined
in trastuzumab-conditioned cell lines.
Tykerb 250mg tablet provide selective Tykerb 250mg action against breast cancer cell lines selected for long-term growth in trastuzumab-containing
intracellularly. HormoneTykerb 250mg tablet receptor-positive breast Tykerb 250mgcancer cells (with ER [Estrogen Receptor] and/or PgR [Progesterone Tykerb 250mg tabletReceptor])
that co express the HER2 bear toTykerb 250mg tablet be protection against established endocrine therapies. Synchronously
hormone receptor-positive Tykerb 250mg tablet breast cancer cells that initially lack EGFR or HER2 unrecalled these receptor proteins as the
tumor becomes resistant toTykerb 250mg tablet endocrine therapy.

PHARMACOKINETIC

ABSORPTION

                       Poor absorpsTykerb 250mg tablet from the GI tract. peak plasma concentration is approx 4hrs ; Tykerb 250mg bioavailability is 95%. Tykerb 250mg with food Tykerb 250mg tabletwill increase the systemic exposure.

DISTRIBUTION

                     Plasma Tykerb 250mg protein binding is 99%

METABOLISM

                  Tykerb 250mg tablet Metabolized mainly Tykerb 250mg by CYP3A4 and CYP3A5.

ELIMINATION

The Tykerb 250mg drug eliminatedTykerb 250mg tablet dose via feces more than 14% and <2% urine.
Eliminated half life is 24hrs.

PRODUCT DETAILS

Brand : Tykerb
Ingredients : Lapatinib
Strength : 250mg
Manufactured : Novartis India Ltd
Package : 30 Tablets
PRICE:Tykerb 250mg tablet ,Tykerb 250mg

DOSAGE AND ADMINISTRATION

                   The usual Tykerb 250mg tabletdose of Tykerb for adult suffering HER2 positive metastatic breast cancer
(with xeloda) is 1250mg Tykerb 250mg tabletonce daily for 1-21daysTykerb 250mg tablet continuously repeating.
Femara Combination with Tykerb the dose recommended is 1500mg orally once Tykerb 250mg tableta day continuosly once daily every day.
Take the Tykerb 250mg drug Tykerb tablet on Tykerb 250mg tabletan empty stomach(1hr before or 1hr after).

OVERDOSE

                    If overdose occurs, Tykerb 250mg tabletseek to emergency department or call poison control helpline

SIDE EFFECTS

                Tykerb 250mg tablet will cause mild to moderate side effects in patients. If symptoms causes Tykerb 250mg tabletserious theTykerb 250mg  inform the doctor as Tykerb 250mg tabletsoon as possible.

COMMON SIDE EFFECT OF TYKERB 250MG TABLET

                    Lumbar pain;Tykerb 250mg tablet diarrhae; dry skin; nail of finger toe changes; headache; in digestion problem ; Tykerb 250mg tabletdecreased appetite; mild hair loss or thinning;
mouth ulcers; nausea; nosebleed; Tykerb 250mg tabletredness and hands and Tykerb 250mg feet will have tingling; weakness; insomnia; vomiting.

SERIOUS SIDE EFFECT OF TYKERB 250MG TABLETS

                      Severe tightness;Tykerb 250mg tablet difficulty in breathing; unusual bruising or bleeding; unusual itching; yellowing of the eyes or skin;.
Chest pain; urine Tykerb 250mg tabletwill be dark; Tykerb 250mg dizziness or light-headedness; Tykerb 250mg Rapid or irregular heartbeat; pale stools; persistent loss of appetite;
severe or Tykerb 250mg tabletpersistent cough; severe or persistent diarrhea,



nausea, Tykerb 250mg tabletvomiting and skin allergy like itching, rashes, blisters in mouth, face,Tykerb 250mg tablet lip or tongue.

SAFETY PRECAUTIONS

                     If you are Tykerb 250mg tablet allergic to lapatinib, then do not use the drug
If you had hepatic problem, Tykerb 250mg cardio disease, an electrolytic imbalance then discuss with doctor whether it’s safe to use or not piror to Tykerb treatment.
While patients Tykerb 250mg during pregnancy,Tykerb 250mg it should strictly avoid the drug because it harm the unborn baby or cause birth defects.
There is not known whether Tykerb 250mg Lapatinib passes into breast milk. Hence avoid breast feeding to the infants during Tykerb treatment,

DRUG INSTRUCTION

                  Interation of Tykerb 250mg tablet with following drugs: Artemether,Etravirine,Pazopanib, Tracrolimus,Tykerb 250mg tablet Telithromycin,Topotecan,Tykerb 250mg tabletTramadol,Tretinoin, Tykerb 250mg Voriconazole, Ziprasidone. will increase risk of side effects and drug will not work properily and effect of Tykerb may changes.

PREGNANCY

                 Tykerb 250mg tablet has no adequate and well tolerated details about the drug Tykerb 250mg in Tykerb 250mg tablet pregnantTykerb 250mg women. Excretion into human milk is unknown. Avoid not become pregnant Tykerb 250mg tablet while receiving Tykerb treatment.

CONTRAINDICATION

                Tykerb 250mg is contraindicated Tykerb 250mg tablet to hypersensitivity condition Tykerb 250mg tablet and any products of recipients of Tykerb

STORAGE

                Do Tykerb 250mg not use the drug Tykerb 250mg tablet after the medication has expired. Keep away from the children. For Discarding the medicine, Tykerb 250mg it should discuss with pharmacist.Tykerb 250mg tablet for proper dispose of chemo drugs. Store at 25-30°C.

MISSED DOSE

                Take the missed Tykerb 250mg tablet dose as you remember soon Tykerb 250mg tablet before the next dose time. If time to next dose then skip the missed dose and go Tykerb 250mg tablet for daily Tykerb 250mg tablet schedule, don’t make up with extra dose. Please consult the doctorTykerb 250mg  for further details.

EMAIL ID        : millionhealthpharmaceuticals@gmail.com
CONTACT US : +91-9940472902
WEBSITE         : https://millionpharma.com/tykerb.php

KEYWORDS:Tykerb 250mg tablet ,Tykerb 250mg

Erlonat 150 mg (Natco)|Anti cancer Drug|uses,side effects,price India

                           ERLONAT

DESCRIPTION

                              Erlonat 150mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 150mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor. 

Erlonat tablets are prescription medicine, used only by the patients who have valid prescription

Erlonat 150mg

INDICATION AND USAGE

                             Erlonat 150mg tablet is primarily indicated for; Non small cell lung cancer: Erlonat is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat is involved in the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlonat 150mg tabletis not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat is used in combination with gemcitabine. In this condition Erlonat 150mg is involved as first line treatment.

WARNING

                   Some of the adverse effects occur while treating with Erlonat tablets; Interstitial lung disease Renal impairment Hepatic toxicity with liver failure Gastrointestinal perforation Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular disorders Embryo fetal toxicity

ERLONAT PHARMACOLOGY

                    Erlonat 150mg tablethas pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ERLONAT ADME PROPERTY

ABSORPTION

                    The peak plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlonat , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

                    Volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%.

METABOLISM

                  The metabolism of Erlotinib is occurs by CYP3A4

ELIMINATION

             The route of elimination of Erlotinib metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

PRODUCT DETAILS

Brand : Erlonat 

Ingredients : Erlotinib 

Strength : 150mg 

Manufactured : Natco 

Package : 30 Tablets 

DOSAGE MANAGEMENT

In NSCLC: The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat is 100mg should be taken as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlonat therapy In severe hepatic failure: Stop the therapy permanently 

In renal impairment: Discontinue the Erlonat therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently. Avoid concomitant use of Erlonat with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SOME SERIOUS ADVERSE EFFECT

               Renal failure Liver toxicity with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

                   Rash Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with lipid lowering drugs

CYP3A4 INHIBITORS:

                  Concomitant use of Erlonat with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat . 

IN CYP3A4 INDUCERS:

               In combination of Erlonat with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlonat .

CYP1A2 INDUCERS & CIGARETTE SMOKING:

                      Both are decreasing the exposure of Erlotinib, while concomitant with Erlonat . 

GASTRIC REGULATORS:

            While concomitant with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib. 

ANTICOAGULANTS:

                  In combination of Erlonat with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

EMAIL ID        :millionhealthpharmaceuticals@gmail.com

CONTACT US :+91-9940472902

WEBSITE        :https://millionpharma.com/erlonat.php

Erlonat 150 mg (Natco)|Anti cancer Drug|uses,side effects,price India

                             ERLONAT

DESCRIPTION

Erlonat 150mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 150mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor. 

Erlonat 150mg tablets are prescription medicine, used only by the patients who have valid prescription

Erlonat 150mg

INDICATION AND USAGE 

                           Erlonat 150mg is primarily indicated for; Non small cell lung cancer: Erlonat 150mg tablet is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat is involved in the treatment of non-small cell lung cancer patients whose cancer cells Erlonat 150mg  tablets containing epidermal growth factor receptors on their surface. Erlonat 150mg is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat Erlonat 150mg  tablets is used in combination with gemcitabine. In this condition Erlonat is involved as first line treatment.

WARNING

                            Some of the adverse effects occur while treating with Erlonat 150mg  tablets; Interstitial lung disease Renal impairmentErlonat 150mg  tablets Hepatic toxicity with liver failure Gastrointestinal perforation Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular Erlonat 150mg  tablets disorders Embryo fetal toxicity 

ERLONAT PHARMACOLOGY

                         Erlonat has pharmacological effectsErlonat 150mg  tablets like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factorErlonat 150mg  tablets receptor. This EGFR is occursErlonat 150mg  tablets on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

           ERLONAT ADME PROPERTY

ABSORPTION

                    The peak plasma concentration Erlonat 150mg  tablets time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its bioavailability to 100%. The Erlotinib 1 Erlonat 150mg  tablets solubility is dependsErlonat 150mg  tablets upon pH level. The reduction in solubility causes elevation of the Erlonat 150mg  tablets pH levels. Smoking should Erlonat 150mg  tablets be avoided during the treatment with Erlonat 150mg , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

                  Volume of distribution Erlonat 150mg  tablets of Erlotinib is 232L Human protein binding to Erlotinib 150mg tablet is occurs as 93%.

METABOLISM

                    The metabolism of Erlotinib isErlonat 150mg  tablets  occurs by CYP3A4

ELIMINATION

The route of elimination of ErlotinibErlonat 150mg  tablets metabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

                PRODUCT DETAILS

Brand : Erlonat 

Ingredients : Erlotinib 

Strength : 150mg 

Manufactured : Natco 

Package : 30 Tablets 

DOSAGE ADMINISTRATION

DOSAGE MANAGEMENT

                                     In NSCLC: Erlonat 150mg  tablets The recommended dosage is 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat is 100mg should be taken as a Erlonat 150mg  tablets  single dose by administering on an empty stomachErlonat 150mg  tablets by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Interstitial lung disease, pulmonary failure: Discontinue the Erlonat therapy In severe hepatic failure: Stop the therapy permanently 

                                    In renal impairment: Discontinue the Erlonat 150mg therapy permanently In gastrointestinal perforation and severe diarrhea: Stop the therapy In severe Bullous and exfoliative skin disorders: Erlonat 150mg  tablets Discontinue the therapy and provide supportive measures In corneal perforation, therapy should be discontinuing permanently.Erlonat 150mg  tablets Avoid concomitant use of Erlonat with Erlonat 150mg  tablets CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECTS

SOME SERIOUS ADVERSE EFFECT

                                  Renal failure Erlonat 150mg  tablets Liver toxicity with failure Gastrointestinal perforations Ocular disorders HemorrhageErlonat 150mg  tablets Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

                                  Rash Diarrhea Erlonat 150mg  tablets Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Chest pain, arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while Erlonat 150mg  tablets combining with lipid lowering drugs

DRUG INTERCTION

CYP3A4 INHIBITORS:

                               Concomitant use of Erlonat 150mg tablet with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir, Erlonat 150mg  tablets posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) Erlonat 150mg  tablets causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat . 

IN CYP3A4 INDUCERS:

                            In combination ofErlonat 150mg  tablets Erlonat with CYP3A4Erlonat 150mg  tablets inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeuticErlonat 150mg  tablets effect of Erlonat .

CYP1A2 INDUCERS & CIGARETTE SMOKING:

                          Both are decreasingErlonat 150mg  tablets the exposure of Erlotinib, while concomitant with Erlonat . 

GASTRIC REGULATORS:

                       While concomitant Erlonat 150mg  tablets with gastric regulators like proton pump inhibitors, H2 receptors antagonist or antacids, causes depletion of Erlotinib Erlonat 150mg  tablets exposure leads to loss of therapeutic effect of Erlotinib. 

ANTICOAGULANTS:

                       In combination of Erlonat 150mg  tablets Erlonat with warfarin, causes increasing international normalizedErlonat 150mg  tablets ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

Email id    :millionhealthpharmaceuticals@gmail.com

Contact us :+91-9940472902

Website      :https://millionpharma.com/erlonat.php

Votrient 400mg - Anticancer drugs | view uses, side effects and price | MHP

                              PAZOPANIB 400MG

DESCRIPTION

                              pazopanib 400mg (pazopanib) is a type of protein kinase inhibitors. It is also indicated for the treatment of advanced kidney cancer and soft tissue sarcoma

  pazopanib 400mg tablet is an antineoplastics medications which interfere with the development and spreadness of cancer cells in the body.

    pazopanib 400mg 

                                   USAGE

  pazopanib 400mg tablet is an effective inhibitor of protein kinase and selective multiple receptor tyrosine kinases (RTKs) that are described in beginning of signal transduction pathways that ready for reproduction of tumor cells and affect processes critical to cell survival and tumor progression. RTKs comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3), platelet-derived growth factors (PDGFR-α and -β), and stem cell factor.

                          MECHANISM OF ACTION

  pazopanib 400mg tablet is an effective inhibitor of protein kinase and selective multiple receptor tyrosine kinases (RTKs) that are described in beginning of signal transduction pathways that ready for reproduction of tumor cells and affect processes critical to cell survival and tumor progression. RTKs comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3), platelet-derived growth factors (PDGFR-α and -β), and stem cell factor

                           PHARMACOKINETIC

ABSORPTION

                           Fast GI absorption with food and Bioavailability is 14-39%. Time of high plasma concentration: 2-4 hr.

DISTRIBUTION

                        bounding of human protein of pazopanib 400 mg is >99%.

METABOLISM

                       Mainly in the liver pazopanib 400 mg metabolized by CYP3A4 enzyme and to a lesser extent by CYP1A2 and CYP2C8 enzymes.

ELIMINATION

                       pazopanib primarily excreted through faces approx 82%, 67% as unchanged drug and urine (<4%)with renal elimination. Terminal Elimination half-life: Approx 31 hr.

PRODUCT DETAILS

Brand : Votrient
Ingredients : Pazopanib
Strength : 400mg
Manufactured : GlaxoSmithKline Pharmaceuticals
Package : 30 Tablets

DOSAGE & ADMINISTARTION

                 pazopanib 400mg tablet dosage for renal cell carcinoma and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 400 mg increments or decrements dose based on tolerance but max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient dose of 400 mg once daily.   pazopanib 400mg should be taken on a empty stomach (1hr before or 2hr after meals. Swallow the medicine whole don’t chew/crush. Food interaction :Avoid grapefruit juice or grapefruit juice.

OVERDOSAGE

                         overdose of the drug can be upto 2000mg can be administrated and It is evaluated in clinical trials and treatment of overdose with votrient should consist of supportive measures and there is no specific antidote.

DOSAGE & ADMINISTARTION

                         pazopanib 400mg  dosage for renal cell carcinoma and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 400 mg increments or decrements dose based on tolerance but max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient dose of 400 mg once daily. The   pazopanib 400mg tablet should be taken on a empty stomach (1hr before or 2hr after meals. Swallow the medicine whole don’t chew/crush. Food interaction :Avoid grapefruit juice or grapefruit juice.

OVERDOSAGE

                      overdose of the drug can be upto 2000mg can be administrated and It is evaluated in clinical trials and treatment of overdose with votrient should consist of supportive measures and there is no specific antidote.

Email id    :millionhealthpharmaceuticals@gmail.com
contact us :+91-9940472902
Wedsite     :https://millionpharma.com/votrient-400mg.php

Votrient 200mg - Anticancer drugs | view uses, side effects and price | MHP

               VOTRIENT 200MG

DESCRIPTION

                                       Votrient 200mg tablet(pazopanib) is a type Votrient 200mg tabletof protein kinase inhibitors. It is also indicated for the Votrient 200mg tablet treatment of advanced kidney cancer and soft tissue sarcoma

                                    Votrient 200mg is an antineoplastics Votrient 200mg tabletmedications which interfere with the development and spreadness Votrient 200mg tablet of cancer cells in the body

votrient 200mg

USAGE

            Votrient 200mg is used as a single agent toVotrient 200mg tablet treat the renel cell carcinoma and its advanced stage It works by preventing the activity of proteins which are interferes with the growth and spread Votrient 200mg tabletof cancer cells. Votrient 200mg tablet is also used Votrient 200mg tabletas a single regimen to Votrient 200mg tablet treat the Soft Tissue Sarcoma, (a type of cancer that occurs in the supportive tissue of the body). The cancer can develop in muscles, Votrient 200mg tabletblood vessels, fat tissue Votrient 200mg tabletor in other tissues that support, surround and protect organs

MECHANISM OF ACTION

            Votrient 200mg is an effective inhibitor ofVotrient 200mg tablet protein kinase and selective multiple receptor tyrosine kinases (RTKsVotrient 200mg tablet that are described at the beginning of Votrient 200mg tablet signal transduction pathways that ready for the reproduction of tumor cells and affect processes critical to Votrient 200mg tabletcell survival andVotrient 200mg tablet tumor progression. RTKsVotrient 200mg tablet comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3),Votrient 200mg tablet platelet-derived growth Votrient 200mg tablet factors (PDGFR-α and -β), and stem cell factor. 

                                        

PHARMACOKINETIC

ABSORPTION

               Fast GI absorption Votrient 200mg tablet with food and Votrient 200mg tabletBioavailability is 14-39%. Votrient 200mg tabletTime of high plasma concentration: 2-4 hr.

DISTRIBUTION

                        bounding of humanVotrient 200mg tablet protein of pazopanib 200mg is >99%.

METABOLISM

                      Mainly in the liver pazopanib Votrient 200mg tablet 200mg metabolized by CYP3A4 enzyme and to a lesser extent by CYP1A2 and CYP2C8 enzymes.

ELIMINATION

                      pazopanib primarily Votrient 200mg tabletexcreted through faeces approx 82%, 67% as unchanged drug and urine (<4%)with renal elimination. Votrient 200mg tabletTerminal Elimination half-life: Approx 31 hr.

                            PRODUCT DETAILS

Brand : Votrient 
Ingredients : Pazopanib 
Strength : 200mg 
Manufactured : GlaxoSmithKline Pharmaceuticals 
Package : 30 Tablets 

DOSAGE AND ADMINISTARTION

                    Votrient Votrient 200mg tabletdosage for renal cell carcinomaVotrient 200mg tablet and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 200mg increments or decrements dose based on tolerance Votrient 200mg tabletbut max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient dose of 200mg once daily. Votrient 200mg tablet Votrient should be Votrient 200mg tablet taken on a empty stomachVotrient 200mg tablet (1hr before or 2hr after meals. Swallow theVotrient 200mg tablet medicine whole don’t chew/crush. Food interaction :Votrient 200mg tablet Avoid grapefruit juice or grapefruit juice.

OVERDOSAGE

                       overdose Votrient 200mg tablet of the drug can be upto 2000mg can be administrated and It is evaluated in clinical trials Votrient 200mg tablet and treatment of overdose with votrient should consist of Votrient 200mg tablet supportive measures and there is no specific antidote.

SIDE EFFECTS

                  Votrient 200mg tablet has certain side effects,Votrient 200mg tablet If any of the symptoms occrs or not cured then call the doctor immediately

MAJOR SIDE EFFECTS

            Diarrhae; High blood pressure; Votrient 200mg tabletlow WBC; Elevated liver function test; Blood test abnormalities; increased Votrient 200mg tablet in bilirubin levels.

COMMON SIDE EFFECTS:

                     Nausea;Votrient 200mg tablet  loss of appetite; fatigue; blood test abnormalities (low magnesium, low glucose); weakness, Votrient 200mg tablet stomach ache.

contact us:

EMAIL ID    : millionhealthpharmaceuticals@gmail.com

PHONE NO : +91-9940472902

WEBSITE    :https://millionpharma.com/votrient-200mg.php